Aslani, Iris .
HRN: 24-25-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/13/2024
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
05/13/2024
05/20/2024
PO
1ml
QID
Oral Candidiasis
Waiting Final Action
Indication: Empiric Then Culture-directed Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes